Welcome to our dedicated page for Brainstorm Cell Therapeutics I news (Ticker: BCLI), a resource for investors and traders seeking the latest updates and insights on Brainstorm Cell Therapeutics I stock.
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI) delivers innovative autologous stem cell therapies targeting neurodegenerative diseases through its NurOwn® platform. This dedicated news hub provides investors and healthcare stakeholders with timely updates on clinical developments, regulatory progress, and strategic initiatives.
Access authoritative reporting on key milestones including clinical trial results, FDA communications, manufacturing partnerships, and scientific presentations. Our curated news collection enables efficient tracking of BCLI's progress in advancing treatments for ALS, multiple sclerosis, and Parkinson's disease.
Key content categories include:
- Clinical trial phase updates
- Regulatory submissions and designations
- Research collaborations
- Peer-reviewed publication highlights
- Financial reporting
Bookmark this page for consolidated access to verified BCLI developments. Check regularly for updates on novel cellular therapies addressing critical unmet medical needs in neurology.
BrainStorm Cell Therapeutics (NASDAQ: BCLI) reported its financial results for the first quarter ended June 30, 2021, indicating a net loss of approximately $6.3 million, down from $7.4 million the previous year. Cash and equivalents totaled around $35.0 million, a decline from $40.0 million as of March 31, 2021. The company successfully received GMP approval for expanded manufacturing capacity in Israel and has strengthened its NurOwn® intellectual property with multiple patents in key markets. Ongoing discussions with ALS experts aim to enhance the regulatory strategy for NurOwn.
BrainStorm Cell Therapeutics (NASDAQ: BCLI) has received GMP approval from the Israel Ministry of Health for three advanced cleanrooms at Sourasky Hospital, doubling its manufacturing capacity for NurOwn®. This expansion is crucial for supplying ALS patients in Israel and Europe, addressing an urgent need for new therapies. The company remains committed to advancing its cellular technology for neurodegenerative diseases, with ongoing discussions on regulatory pathways for NurOwn®.
BrainStorm Cell Therapeutics (BCLI) will conduct a conference call on August 5, 2021, at 8:00 a.m. ET, to discuss second-quarter financial results ending June 30, 2021, and provide a corporate update. CEO Chaim Lebovits will lead the call, supported by key executives, and encourage shareholders to submit questions by August 4, 2021.
This call aims to enhance transparency with investors and will be accessible via dial-in numbers and a webcast link.
Brainstorm Cell Therapeutics Inc. (NASDAQ: BCLI) announced the grant and allowance of several patents for its NurOwn® technology aimed at treating neurodegenerative diseases. These patents, effective across major markets including the U.S., E.U., Canada, Israel, and Hong Kong, strengthen Brainstorm's intellectual property portfolio. CEO Chaim Lebovits emphasized the significant potential of NurOwn in addressing unmet medical needs, particularly for diseases like ALS and MS. The company's innovative MSC-NTF cell therapy has received Orphan Drug designation from the FDA and EMA.
On May 25, 2021, BrainStorm Cell Therapeutics (NASDAQ: BCLI) presented new findings regarding its MSC-NTF (NurOwn®) technology at ISCT 2021. The study demonstrated that NurOwn exosomes significantly improve lung parameters in a mouse model of ARDS, a severe complication of COVID-19. Key improvements included a reduction in pro-inflammatory cytokines and lung damage markers. The enhanced protein cargo in MSC-NTF exosomes was noted as a potential factor for their efficacy. CEO Chaim Lebovits highlighted the strategic focus on ARDS as an unmet medical need while progressing with their ALS and MS therapeutic pipeline.
BrainStorm Cell Therapeutics (BCLI) announced Q1 2021 financial results and significant progress in its clinical trials. The Phase 2 trial of NurOwn® for progressive multiple sclerosis achieved primary safety endpoints, showing clinically meaningful improvements compared to matched cohorts. Cash reserves stood at approximately $40 million. R&D expenses decreased to $4.3 million from $5.9 million YoY, while the net loss shrank to $6.6 million, or $0.19 per share, down from $8.1 million, or $0.32 per share, in Q1 2020. A corporate update highlights ongoing efforts in ALS treatment development and regulatory strategy.
BrainStorm Cell Therapeutics Inc. (BCLI) will hold a conference call on April 26, 2021, at 8:00 a.m. ET to disclose financial results for Q1 2021, which ended on March 31, 2021. CEO Chaim Lebovits will provide updates, followed by a Q&A session. The company focuses on cellular therapies for neurodegenerative diseases, particularly its NurOwn® technology platform, which has received FDA and EMA Orphan Drug designations for treating ALS. The Phase 3 trial for ALS has been completed, with a Phase 2 trial for MS also underway.
BrainStorm Cell Therapeutics (NASDAQ: BCLI) announced positive topline data from its Phase 2 trial of NurOwn® for progressive multiple sclerosis (MS). The trial met its primary endpoint for safety and demonstrated improvements in secondary outcomes, including neurologic function and cognition. Of the 20 enrolled patients, 16 completed the study, with significant enhancements in measures like the timed 25-foot walk test and cognitive processing tests. The results suggest NurOwn® has potential as a therapeutic option for progressive MS, urging further evaluations and data presentation at scientific meetings.
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI) announced participation in the 10th Annual SVB Leerink Global Healthcare Conference on February 26, 2021. Dr. Stacy Lindborg, EVP and head of Global Clinical Research, will present a corporate update at 8:40 AM Eastern Time. A live webcast of the presentation can be accessed via the provided link. The company focuses on developing adult stem cell therapies for neurodegenerative diseases. Caution is advised regarding forward-looking statements about clinical trials and financial requirements.
BrainStorm Cell Therapeutics (BCLI) announced that it received initial feedback from the FDA regarding the clinical data from its NurOwn ALS Phase 3 trial. The FDA indicated that the current data does not meet the criteria needed for a Biologics License Application (BLA). However, the FDA's stance allows BrainStorm to still pursue a BLA submission. The company, well-funded with over $40M in cash, plans to consult with ALS experts and stakeholders before making a decision on the BLA submission. They aim to analyze data further and communicate findings in a peer-reviewed publication.
